US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
DE102004029784A1
(en)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
|
DE102004033670A1
(en)
*
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New pyridodihydropyrazinone, process for its preparation and its use as a medicament
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
EP1630163A1
(en)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinones, methods for their preparation and their use as drugs
|
EP1632493A1
(en)
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridine derivatives, methods for their preparation and their use as drugs
|
CA2578560A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for the production thereof, and use thereof as a medicament
|
US7713973B2
(en)
|
2004-10-15 |
2010-05-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
DE102004058337A1
(en)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of fused piperazin-2-one derivatives
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
SI1948180T1
(en)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
AU2012256410B2
(en)
*
|
2006-02-08 |
2016-04-28 |
Boehringer Ingelheim International Gmbh |
Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
DE602007008837D1
(en)
|
2006-02-14 |
2010-10-14 |
Vertex Pharma |
AS PROTEIN KINASE INHIBITORS USEFUL DYHYDRODIAZEPINE
|
WO2007135374A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Astrazeneca Ab |
Dihydropteridine compounds as anti proliferative agents
|
TW200808325A
(en)
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
JP2010505962A
(en)
|
2006-10-09 |
2010-02-25 |
武田薬品工業株式会社 |
Kinase inhibitor
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
NZ576278A
(en)
|
2006-10-19 |
2011-12-22 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
MX2009006345A
(en)
|
2006-12-14 |
2009-06-23 |
Vertex Pharma |
Compounds useful as protein kinase inhibitors.
|
EP2815750A1
(en)
|
2006-12-21 |
2014-12-24 |
Vertex Pharmaceuticals Incorporated |
5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
|
EP1953163A1
(en)
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
US8329695B2
(en)
|
2007-08-03 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
|
EP2205603B1
(en)
|
2007-09-28 |
2014-01-15 |
Cyclacel Limited |
Pyrimidine derivatives as protein kinase inhibitors
|
US20090291938A1
(en)
*
|
2007-11-19 |
2009-11-26 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
EP2215091B1
(en)
*
|
2007-12-04 |
2016-03-30 |
Nerviano Medical Sciences S.r.l. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
GB0807452D0
(en)
*
|
2008-04-24 |
2008-05-28 |
Chroma Therapeutics Ltd |
PLK inhibitors
|
WO2010008459A1
(en)
*
|
2008-06-23 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors
|
US9492417B2
(en)
|
2008-08-21 |
2016-11-15 |
The Johns Hopkins University |
Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
|
US20100075973A1
(en)
*
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
KR101787309B1
(en)
|
2008-12-09 |
2017-10-18 |
길리애드 사이언시즈, 인코포레이티드 |
Modulators of toll-like receptors
|
EP3255047B1
(en)
*
|
2009-01-06 |
2021-06-30 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
|
RS57869B1
(en)
|
2009-06-17 |
2018-12-31 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
ES2661850T3
(en)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Toll type receiver modulators
|
CN102020643A
(en)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
dihydropteridine ketone derivative, and preparation method and medicinal application thereof
|
AU2010298190A1
(en)
|
2009-09-25 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
JP2013505927A
(en)
|
2009-09-25 |
2013-02-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Method for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
EP3091021B1
(en)
|
2009-10-26 |
2019-08-28 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
AU2010336509A1
(en)
*
|
2009-12-23 |
2012-07-19 |
Elan Pharmaceuticals, Inc |
Pteridinones as inhibitors of polo-like kinase
|
EP2536725B1
(en)
|
2010-02-17 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, method for production and use thereof
|
CN102190669A
(en)
*
|
2010-03-19 |
2011-09-21 |
江苏恒瑞医药股份有限公司 |
Dihydro pteridinone derivatives, preparation method thereof and application thereof in medicines
|
US8609672B2
(en)
|
2010-08-27 |
2013-12-17 |
University Of The Pacific |
Piperazinylpyrimidine analogues as protein kinase inhibitors
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
KR20140014110A
(en)
|
2010-12-16 |
2014-02-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Inhibitors of influenza viruses replication
|
US20130131069A1
(en)
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
UA118010C2
(en)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
INFLUENCES OF INFLUENZA VIRUS REPLICATION
|
TWI708605B
(en)
|
2011-10-19 |
2020-11-01 |
標誌製藥公司 |
Treatment of cancer with tor kinase inhibitors
|
WO2013071217A1
(en)
*
|
2011-11-10 |
2013-05-16 |
OSI Pharmaceuticals, LLC |
Dihydropteridinones
|
EA026390B1
(en)
|
2011-12-02 |
2017-04-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, SOLID FORMS THEREOF AND METHODS OF THEIR USE
|
JP5807750B2
(en)
*
|
2012-01-05 |
2015-11-10 |
トヨタ自動車株式会社 |
Fastening device and fastening method
|
US9006226B2
(en)
|
2012-02-23 |
2015-04-14 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones I
|
US8865716B2
(en)
|
2012-02-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones II
|
EP2817029B1
(en)
|
2012-02-24 |
2019-07-10 |
Signal Pharmaceuticals, LLC |
Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
US20140154304A1
(en)
|
2012-11-30 |
2014-06-05 |
Boehringer Ingelheim International Gmbh |
Combination therapy with volasertib
|
US9346812B2
(en)
|
2013-01-16 |
2016-05-24 |
Signal Pharmaceuticals, Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
JP6052527B2
(en)
*
|
2013-02-21 |
2016-12-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dihydropteridinone I
|
JP6072308B2
(en)
*
|
2013-02-21 |
2017-02-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dihydropteridinone II
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
NZ629230A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
MX2015014455A
(en)
|
2013-04-17 |
2016-07-21 |
Signal Pharm Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-yl amino)phenyl)acrylamide for treating cancer.
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
AU2014253978B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
|
NZ629332A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
CA2908830C
(en)
|
2013-04-17 |
2021-12-07 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
JP6401250B2
(en)
|
2013-05-29 |
2018-10-10 |
シグナル ファーマシューティカルズ,エルエルシー |
7- (6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1-((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 (1H) -one, pharmaceutical composition thereof in solid form, and method of use thereof
|
US20150031699A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
SI3068782T1
(en)
|
2013-11-13 |
2018-10-30 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing inhibitors of influenza viruses replication
|
JP6615755B2
(en)
|
2013-11-13 |
2019-12-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Inhibitors of influenza virus replication
|
JP2017504651A
(en)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Use of diazepan derivatives
|
JP2017512186A
(en)
*
|
2014-01-31 |
2017-05-18 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Dihydropteridinone derivatives and uses thereof
|
US9737535B2
(en)
|
2014-04-16 |
2017-08-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
CN104003989B
(en)
|
2014-05-26 |
2015-11-11 |
苏州明锐医药科技有限公司 |
Fu Lasai for and the preparation method of intermediate
|
US11116774B2
(en)
|
2014-07-11 |
2021-09-14 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of HIV
|
US9623028B2
(en)
|
2014-07-14 |
2017-04-18 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
WO2016022902A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
CA2955077A1
(en)
*
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
EA201790369A1
(en)
|
2014-09-16 |
2017-10-31 |
Джилид Сайэнс, Инк. |
SOLID FORMS OF THOUGH-RECEPTOR MODULATOR
|
EA201790373A1
(en)
|
2014-09-16 |
2017-08-31 |
Джилид Сайэнс, Инк. |
METHODS OF OBTAINING MODULATORS OF TOLL-SIMILAR RECEPTORS
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
JP6857617B2
(en)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Influenza virus replication inhibitor
|
EP3294717B1
(en)
|
2015-05-13 |
2020-07-29 |
Vertex Pharmaceuticals Inc. |
Methods of preparing inhibitors of influenza viruses replication
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
RU2750164C2
(en)
|
2015-09-11 |
2021-06-22 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Cyanothienotriazolodiazepines and methods for their use
|
KR20180051576A
(en)
|
2015-09-11 |
2018-05-16 |
다나-파버 캔서 인스티튜트 인크. |
Acetamide thienotriazolol diazepines and their uses
|
EP3370712A4
(en)
|
2015-11-06 |
2019-10-09 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
WO2017091673A2
(en)
|
2015-11-25 |
2017-06-01 |
Dana-Farber Cancer Institute, Inc. |
Bivalent bromodomain inhibtors and uses thereof
|
CN105801582A
(en)
*
|
2016-04-12 |
2016-07-27 |
合肥工业大学 |
Novel dihydro pteridinone derivative, preparing method thereof and application to medicine
|
DE102017005089A1
(en)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituted 3,4-dihydroquinoxaline-2 (1H) -one
|
DE102017005091A1
(en)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
|
CN106977584B
(en)
*
|
2017-04-19 |
2019-12-06 |
吉林大学 |
Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof
|
BR112019027402A2
(en)
|
2017-06-22 |
2020-07-07 |
Celgene Corporation |
treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus
|
CA3080941A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Dana-Farber Cancer Institute, Inc. |
Nek inhibitors and methods of use
|
EP3743067A1
(en)
|
2018-01-25 |
2020-12-02 |
Boehringer Ingelheim International GmbH |
Combination treatment of acute myeloid leukemia
|
US11034669B2
(en)
|
2018-11-30 |
2021-06-15 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
CN110343109B
(en)
*
|
2019-08-21 |
2021-11-23 |
郑州大学 |
Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof
|
WO2023196943A1
(en)
|
2022-04-08 |
2023-10-12 |
Inhibrx, Inc. |
Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
|